Safety and efficacy of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases

被引：1
|
作者：
Novello, S. [1 ]
Camps, C. [2 ]
Grossi, F. [3 ]
Mazieres, J. [4 ]
Abrey, L. [5 ]
Fain, J. [6 ]
Patyna, S. [7 ]
Selaru, P. [7 ]
Chao, R. [7 ]
Scagliotti, G. [1 ]
机构：
[1] Univ Turin, Thorac Oncol Unit, Turin, Italy
[2] Univ Gen Hosp Valencia, Valencia, Spain
[3] Natl Inst Canc Res, Genoa, Italy
[4] Hop Larrey, Unite Cancerol Cervico Thorac, Toulouse, France
[5] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[6] Texas Oncol, Hematol Oncol, Austin, TX USA
[7] Pfizer Oncol, Dev, La Jolla, CA USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71866-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：551 / 551
页数：1
相关论文
共 50 条
  • [1] Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results
    Novello, S.
    Camps, C.
    Grossi, F.
    Mazieres, J.
    Abrey, L. E.
    Vernejoux, J.
    Thall, A. D.
    Usari, T.
    Chao, R. C.
    Scagliotti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases
    Novello, Silvia
    Camps, Carlos
    Grossi, Francesco
    Mazieres, Julien
    Abrey, Lauren
    Vernejoux, Jean-Marc
    Thall, Aron
    Patyna, Shem
    Usari, Tiziana
    Wang, Zhixiao
    Chao, Richard C.
    Scagliotti, Giorgio
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (07) : 1260 - 1266
  • [3] A phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases
    Novello, Silvia
    Abrey, Lauren
    Grossi, Francesco
    Camps, Carlos
    Mazieres, Julien
    Fain, Jerry
    Vernejoux, Jean-Marc
    Carpeno, Javier de Castro
    Selaru, Paulina
    Patyna, Shem
    Torigoe, Yasuhiro
    Chao, Richard
    Scagliotti, Giorgio
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S356 - S356
  • [4] Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial
    Novello, S.
    Abrey, L. E.
    Grossi, F.
    Camps, C.
    Mazieres, J.
    Selaru, P.
    Patyna, S.
    Torigoe, Y.
    Chao, R.
    Scagliotti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Efficacy and safety of bevacizumab in nonsquamous non-small cell lung cancer with brain metastases.
    Ichiki, Masao
    Yoshida, Tsukasa
    Nakamura, Masayuki
    Kumano, Tomomi
    Hoshino, Tomoaki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
    Kevin C. De Braganca
    Yelena Y. Janjigian
    Christopher G. Azzoli
    Mark G. Kris
    Maria C. Pietanza
    Craig P. Nolan
    Antonio M. Omuro
    Andrei I. Holodny
    Andrew B. Lassman
    Journal of Neuro-Oncology, 2010, 100 : 443 - 447
  • [7] Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
    De Braganca, Kevin C.
    Janjigian, Yelena Y.
    Azzoli, Christopher G.
    Kris, Mark G.
    Pietanza, Maria C.
    Nolan, Craig P.
    Omuro, Antonio M.
    Holodny, Andrei I.
    Lassman, Andrew B.
    JOURNAL OF NEURO-ONCOLOGY, 2010, 100 (03) : 443 - 447
  • [8] Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer
    Teng, F.
    Sun, D.
    Xing, P.
    Hao, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S385 - S385
  • [9] Data Show Antitumor Activity With Sunitinib in Patients With Non-Small-Cell Lung Cancer and Irradiated Brain Metastases
    不详
    ONCOLOGY-NEW YORK, 2009, 23 (10): : 856 - 858
  • [10] Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer
    Waqar, Saiama N.
    Waqar, Sadaf H.
    Trinkaus, Kathryn
    Gadea, Carlos A.
    Robinson, Cliff G.
    Bradley, Jeffrey
    Watson, Mark A.
    Puri, Varun
    Govindan, Ramaswamy
    Morgensztern, Daniel
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 36 - 40
12345